Neurimmune today announced that echocardiographic assessments of cardiac function and structure as well as long-term tolerability data from the open-label extension of the Phase I trial of cliramitug (formerly NI006, ALXN2220) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) will be presented at the ESC Congress 2025 in Madrid.
Presentation Details:
Title: Echocardiographic assessments of ventricular function and cardiac structure with ALXN2220, an ATTR depleter: analysis from the open-label extension of study NI006-101
Presenter: Fabian aus dem Siepen (University Hospital Heidelberg - Heidelberg, Germany)
Session: Therapeutic Advances in Amyloid Cardiomyopathy
Date: August 31, 2025
Time: 10:55
Location: Science Box 2 (Research Gateway)
Title: Tolerability of continued treatment with ATTR depleter ALXN2220 in the open-label extension of Phase 1 study NI006-101
Presenter: Olivier Lairez (University Hospital of Toulouse - Toulouse, France)
Session: Heart Failure Management in Specific Populations
Date: August 31, 2025
Time: 17:15 – 18:00
Location: Station 3 (Research Gateway)
ATTR-CM is a systemic and potentially life-threatening disease caused by the deposition of misfolded transthyretin (TTR), which presents with progressive heart failure. Despite advances in slowing disease progression, currently there is no available treatment option designed to deplete TTR from the heart to revert cardiac dysfunction.
Cliramitug is an investigational human monoclonal antibody designed to deplete amyloid deposits in ATTR-CM.1,2 In the Study NI006-101, treatment with cliramitug for more than a year was not associated with apparent drug-related serious adverse events, and surrogate markers of cardiac amyloid load indicated cardiac ATTR depletion along with improvement of cardiac biomarkers and function.2
In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca Rare Disease for cliramitug. Neurimmune is responsible for the Phase 1 study (NI006-101) and the Phase 2 follow-on study (NI006-102, EXCEL), on behalf of Alexion. Alexion is responsible for further clinical development, manufacturing, and commercialization of cliramitug, including the ongoing DepleTTR-CM Phase III trial to evaluate the safety and efficacy of cliratmitug in adults with ATTR-CM.
1Garcia-Pavia et al., N Engl J Med 2023; 389(3):239.
2Michalon et al., Nat Commun 2021; 12(1):3142.
About Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. With its Reverse Translational MedicineTM technology, Neurimmune discovered the anti-ATTR antibody cliramitug (formerly NI006, ALXN2220) for ATTR cardiomyopathy, the anti-SOD1 antibody AP-101 for ALS and the anti-NogoA antibody NG004 for spinal cord injury, programs being currently evaluated in clinical trials.
Contact for Media
John Capodanno (US)
john.capodanno@dentonsglobaladvisors.com
Martin Meier-Pfister (Switzerland)
media@neurimmune.com
